Estimation of psycholeptic and psychoanaleptic medicine use in an adult general population sample using the Anatomical Therapeutic Chemical classification.
Little is known about psycholeptic and psychoanaleptic medicine (PM) use in the general population. This study presents prevalence data about PM use. The sample included 4310 individuals aged 20-79 from a general population health examination in a northern German area (participation proportion: 68.8%; Study of Health in Pomerania, SHIP). Medicines taken during the past seven days were assessed from the medicine packages or self-reports and classified according to the Anatomical Therapeutic Chemical (ATC) classification developed by the World Health Organization. In total, 6.3% of the sample reported PM intake, 8.7% of the women and 4.7% of the men. During the past 12 months prior to the health examination, 49.2% of the individuals with PM use consulted a general practitioner but not a neurologist or a psychiatrist. Among the study participants with PM use, 88.8% had one or more mental disorders during lifetime according to a screening questionnaire. It is concluded that considerable proportions of individuals with current PM use exist although lower than may be expected on the basis of the number of individuals with mental disorder in the general population.
John
U
U
Medical Faculty, Institute of Epidemiology and Social Medicine, University of Greifswald, Greifswald, Germany. ujohn@uni-greifswald.de
Baumeister
S E
SE
Völzke
H
H
Grabe
H J
HJ
Freyberger
H J
HJ
Alte
D
D
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000697:Central Nervous System Stimulants / Q000627:therapeutic use*; D004363:Drug Utilization / Q000706:statistics & numerical data; D005194:Family Practice / Q000706:statistics & numerical data; D005260:Female; D005858:Germany; D006801:Humans; D008297:Male; D008403:Mass Screening / Q000706:statistics & numerical data*; D001523:Mental Disorders / Q000188:drug therapy / Q000453:epidemiology; D008875:Middle Aged; D009462:Neurology / Q000706:statistics & numerical data; D011570:Psychiatry / Q000706:statistics & numerical data; D011619:Psychotropic Drugs / Q000627:therapeutic use*; D012017:Referral and Consultation / Q000706:statistics & numerical data; D014600:Utilization Review; D055815:Young Adult
D000697:Central Nervous System Stimulants; D011619:Psychotropic Drugs
Int J Epidemiol. 2001 Oct;30 Suppl 1:S35-40
11759849
Br J Clin Pharmacol. 2005 Sep;60(3):306-10
16120070
Acta Psychiatr Scand Suppl. 2004;(420):55-64
15128388
JAMA. 2004 Jun 2;291(21):2581-90
15173149
Eur J Clin Pharmacol. 2004 May;60(3):199-204
15024533
N Engl J Med. 2005 Jun 16;352(24):2515-23
15958807
Arch Gen Psychiatry. 1988 Dec;45(12):1069-77
2848472
Eur Neuropsychopharmacol. 2005 Aug;15(4):357-76
15961293
Health Aff (Millwood). 2003 May-Jun;22(3):122-33
12757277
Acta Psychiatr Scand Suppl. 2004;(420):47-54
15128387
Soz Praventivmed. 2001;46(3):186-94
11565448
Psychol Med. 2004 May;34(4):597-611
15099415